Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain - Banz, K; Bischoff, H; Brunner, M (Lung cancer, 2011)
et al.